EMA Authorised: Opuviz (aflibercept) — Samsung Bioepis NL B.V.

View source ↗

Summary

Aflibercept-based therapy Opuviz has been authorised in the EU for multiple ocular conditions including wet age-related macular degeneration, macular edema, dia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Complications in the Retina
• Macular Edema
• Retinal Vein Occlusion
• Wet Macular Degeneration

Drugs mentioned

• Opuviz (aflibercept)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion. MAH: Samsung Bioepis NL B.V.. Decision date: 30/06/2026